{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:40:47Z","timestamp":1791567647171,"version":"4.3.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This paper evaluates the effectiveness and safety of XEN63 stent, either standalone or in combination with phacoemulsification, in patients with primary open-angle glaucoma (POAG). Eighty eyes from 80 patients with medically uncontrolled POAG were assigned to undergo XEN63 implant. The primary outcome was the surgical success, defined as an intraocular pressure (IOP) lowering from preoperative values\u2009\u2265\u200920% and an IOP absolute value between 6 and 18\u00a0mmHg, with or without antiglaucoma medications. Forty-three (53.7%) eyes underwent XEN63-standalone and 37(46.2%) eyes a XEN63\u2009+\u2009Phacoemulsification procedure. Success rate was 68.8% (55\/80) eyes in the overall study sample, 69.8% (30\/43) eyes in the XEN63-standalone group; and 67.6% (25\/37) eyes in the XEN63\u2009+\u2009Phaco group (p\u2009=\u20090.6133). Preoperative IOP was significantly lowered from 22.1\u2009\u00b1\u20094.9\u00a0mmHg and 19.8\u2009\u00b1\u20093.7\u00a0mmHg to 14.7\u2009\u00b1\u20095.3\u00a0mmHg and 13.8\u2009\u00b1\u20093.4\u00a0mmHg in the XEN63-standalone and XEN63\u2009+\u2009Phaco groups, respectively (p\u2009&lt;\u20090.0001 each, respectively); without significant differences between them at any of the time-points measured. Preoperative number of ocular-hypotensive drugs was significantly reduced from 2.3\u2009\u00b1\u20090.8 to 0.3\u2009\u00b1\u20090.7 drugs, from 2.5\u2009\u00b1\u20090.7 to 0.3\u2009\u00b1\u20090.7 drugs; and from 2.0\u2009\u00b1\u20090.8 to 0.3\u2009\u00b1\u20090.7 drugs, in the overall, XEN63-standalone, and XEN63\u2009+\u2009Phaco groups, respectively. Regarding safety, 3(42.5%) eyes had transient hypotony at some point during the study, although only in one (1.2%) eye was clinically significant. Four (5.0%) eyes underwent a needling, 4 (5.0%) eyes underwent surgical-bleb-revision, 1 (1.2%) eye required a device replacement and 1 (1.2%) eye a device removal due to maculopathy. XEN63, either alone or in combination with phacoemulsification, significantly lowered IOP and reduced the number of ocular hypotensive medications. The rate of ocular hypotony was relatively high, although it was clinically relevant only in one eye.<\/jats:p>","DOI":"10.1038\/s41598-024-55287-z","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T20:02:14Z","timestamp":1708804934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effectiveness and safety of XEN 63 in patients with primary-open-angle glaucoma"],"prefix":"10.1038","volume":"14","author":[{"given":"Jos\u00e9 Mar\u00eda","family":"Mart\u00ednez-de-la-Casa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Marcos-Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mill\u00e1-Gri\u00f1\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Laborda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Gim\u00e9nez-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Larrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aritz","family":"Urcola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Teus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Perucho-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"key":"55287_CR1","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl, A. et al. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 120, 1268\u20131279 (2002).","journal-title":"Arch. Ophthalmol."},{"key":"55287_CR2","doi-asserted-by":"crossref","unstructured":"European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Azuara Blanco A., Traverso C.E. (eds). Br. J. Ophthalmol. 105 (Suppl 1), 1\u2013169 (2021)","DOI":"10.1136\/bjophthalmol-2021-egsguidelines"},{"key":"55287_CR3","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/S0161-6420(01)00873-9","volume":"108","author":"PR Lichter","year":"2001","unstructured":"Lichter, P. R. et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 108, 1943\u20131953 (2001).","journal-title":"Ophthalmology."},{"key":"55287_CR4","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","volume":"122","author":"PA Newman-Casey","year":"2015","unstructured":"Newman-Casey, P. A. et al. The most common barriers to glaucoma medication adherence: A cross-sectional survey. Ophthalmology 122, 1308\u20131316 (2015).","journal-title":"Ophthalmology"},{"key":"55287_CR5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ophtha.2011.09.043","volume":"119","author":"J Landers","year":"2012","unstructured":"Landers, J., Martin, K., Sarkies, N., Bourne, R. & Watson, P. A twenty-year follow-up study of trabeculectomy: Risk factors and outcomes. Ophthalmology. 119, 694\u2013702 (2012).","journal-title":"Ophthalmology."},{"key":"55287_CR6","doi-asserted-by":"crossref","unstructured":"Jampel, H.D. et al Collaborative Initial Glaucoma Treatment Study Group. Perioperative complications of trabeculectomy in the collaborative initial glaucoma treatment study (CIGTS). Am. J. Ophthalmol. 140, 16\u201322 (2005).","DOI":"10.1016\/j.ajo.2005.02.013"},{"key":"55287_CR7","doi-asserted-by":"publisher","first-page":"e0024","DOI":"10.5041\/RMMJ.10345","volume":"9","author":"L Bar-David","year":"2018","unstructured":"Bar-David, L. & Blumenthal, E. Z. Evolution of glaucoma surgery in the last 25 years. Rambam Maimonides Med. J. 9, e0024 (2018).","journal-title":"Rambam Maimonides Med. J."},{"key":"55287_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/ICU.0b013e32834ff1e7","volume":"23","author":"H Saheb","year":"2012","unstructured":"Saheb, H. & Ahmed, I. I. Micro-invasive glaucoma surgery: Current perspectives and future directions. Curr. Opin. Ophthalmol. 23, 96\u2013104 (2012).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"55287_CR9","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.jcrs.2014.01.032","volume":"40","author":"RA Lewis","year":"2014","unstructured":"Lewis, R. A. Ab interno approach to the subconjunctival space using a collagen glaucoma stent. J. Cataract Refract. Surg. 40, 1301\u20131306 (2014).","journal-title":"J. Cataract Refract. Surg."},{"key":"55287_CR10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/IJG.0000000000000352","volume":"25","author":"A Sheybani","year":"2016","unstructured":"Sheybani, A., Dick, H. B. & Ahmed, I. I. Early clinical results of a novel ab interno gel stent for the surgical treatment of open-angle glaucoma. J. Glaucoma 25, 691\u2013696 (2016).","journal-title":"J. Glaucoma"},{"key":"55287_CR11","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.jcrs.2015.01.019","volume":"41","author":"A Sheybani","year":"2015","unstructured":"Sheybani, A., Lenzhofer, M., Hohensinn, M., Reitsamer, H. & Ahmed, I. I. Phacoemulsification combined with a new ab interno gel stent to treat open-angle glaucoma: Pilot study. J. Cataract Refract. Surg. 41, 1905\u20131909 (2015).","journal-title":"J. Cataract Refract. Surg."},{"key":"55287_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/ceo.13463","volume":"47","author":"M Lenzhofer","year":"2019","unstructured":"Lenzhofer, M. et al. Four-year results of a minimally invasive transscleral glaucoma gel stent implantation in a prospective multi-centre study. Clin. Exp. Ophthalmol. 47, 581\u2013587 (2019).","journal-title":"Clin. Exp. Ophthalmol."},{"key":"55287_CR13","doi-asserted-by":"publisher","first-page":"4796548","DOI":"10.1155\/2020\/4796548","volume":"2020","author":"A Fern\u00e1ndez-Garc\u00eda","year":"2020","unstructured":"Fern\u00e1ndez-Garc\u00eda, A. et al. Comparing medium-term clinical outcomes following XEN\u00ae 45 and XEN\u00ae 63 device implantation. J. Ophthalmol. 2020, 4796548 (2020).","journal-title":"J. Ophthalmol."},{"key":"55287_CR14","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1177\/1120672120952033","volume":"31","author":"C Lavin-Dapena","year":"2021","unstructured":"Lavin-Dapena, C., Cordero-Ros, R., D\u2019Anna, O. & Mogoll\u00f3n, I. XEN 63 gel stent device in glaucoma surgery: A 5-years follow-up prospective study. Eur. J. Ophthalmol. 31, 1829\u20131835 (2021).","journal-title":"Eur. J. Ophthalmol."},{"key":"55287_CR15","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.3390\/jcm10081628","volume":"10","author":"AM Fea","year":"2021","unstructured":"Fea, A. M. et al. Early experience with the new XEN63 implant in primary open-angle glaucoma patients: Clinical outcomes. J. Clin. Med. 10, 1628 (2021).","journal-title":"J. Clin. Med."},{"key":"55287_CR16","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.3390\/jcm11133801","volume":"11","author":"AM Fea","year":"2022","unstructured":"Fea, A. M. et al. Outcomes of XEN 63 device at 18-month follow-up in glaucoma patients: A two-center retrospective study. J. Clin. Med. 11, 3801 (2022).","journal-title":"J. Clin. Med."},{"issue":"23","key":"55287_CR17","doi-asserted-by":"publisher","first-page":"00078","DOI":"10.1016\/j.ogla.2023.05.001","volume":"S2589\u20134196","author":"IM Hussien","year":"2023","unstructured":"Hussien, I. M., De Francesco, T. & Ahmed, I. I. K. Intermediate outcomes of the novel 63 \u03bcm gelatin microstent versus the conventional 45 \u03bcm gelatin microstent. Ophthalmol. Glaucoma S2589\u20134196(23), 00078\u201300079. https:\/\/doi.org\/10.1016\/j.ogla.2023.05.001 (2023).","journal-title":"Ophthalmol. Glaucoma"},{"key":"55287_CR18","doi-asserted-by":"publisher","first-page":"804847","DOI":"10.3389\/fmed.2022.804847","volume":"9","author":"XZ Chen","year":"2022","unstructured":"Chen, X. Z. et al. The outcomes of XEN gel stent implantation: A systematic review and meta-analysis. Front. Med. (Lausanne) 9, 804847 (2022).","journal-title":"Front. Med. (Lausanne)"},{"key":"55287_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12886-022-02502-y","volume":"22","author":"X Yang","year":"2022","unstructured":"Yang, X., Zhao, Y., Zhong, Y. & Duan, X. The efficacy of XEN gel stent implantation in glaucoma: A systematic review and meta-analysis. BMC Ophthalmol. 22, 305 (2022).","journal-title":"BMC Ophthalmol."},{"key":"55287_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/OPTH.S390955","volume":"17","author":"JF Panarelli","year":"2023","unstructured":"Panarelli, J. F. et al. Intraocular pressure and medication changes associated with Xen gel stent: A systematic review of the literature. Clin. Ophthalmol. 17, 25\u201346 (2023).","journal-title":"Clin. Ophthalmol."},{"key":"55287_CR21","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.21037\/atm-20-6354","volume":"8","author":"B Wang","year":"2020","unstructured":"Wang, B. et al. XEN gel implant with or without phacoemulsification for glaucoma: A systematic review and meta-analysis. Ann. Transl. Med. 8, 1309 (2020).","journal-title":"Ann. Transl. Med."}],"updated-by":[{"DOI":"10.1038\/s41598-024-63374-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55287-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55287-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55287-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T12:09:09Z","timestamp":1717589349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55287-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,24]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["55287"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-55287-z","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-024-63374-4","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,24]]},"assertion":[{"value":"8 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-024-63374-4","URL":"https:\/\/doi.org\/10.1038\/s41598-024-63374-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jos\u00e9 Mar\u00eda Mart\u00ednez-de-la-Casa has received funding as consultant from Allergan, Santen, Alcon, Pfizer, Novartis, Thea, B&L, Glaukos, AJL, and VISUfarma, research funding from Santen, Ivantis, Allergan, Pfizer, Glaukos, and Thea, and lecturer funding from Allergan, Santen, Alcon, Pfizer, Novartis, Thea, B&L, Glaukos, and ICare. Maria Teresa Marcos-Parra has received funding as consultant from AbbVie and Allergan. Elena Milla has received funding as consultant from AbbVie, Allergan, Santen, Brill, and Thea. Teresa Laborda has no interests to declare. Rafael Gim\u00e9nez G\u00f3mez has received funding as a lecturer from Abbvie, Santen and Brill. Jos\u00e9 Manuel Larrosa Carrera has received funding as consultant from AbbVie and Johnson&Johnson. Javier Aritz Urcola Carrera has received funding as consultant from AbbVie and Allergan. Miguel \u00c1ngel Teus has received funding as a lecturer from Alcon and funding as consultant from Allergan. Susana Perucho Martinez has received funding as a lecturer from AbbVie, Allergan, Visufarma and Thea.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4561"}}